Changes in pituitary secretion induced by an agonist-antagonist opioid drug, buprenorphine

1983 ◽  
Vol 104 (3) ◽  
pp. 257-260 ◽  
Author(s):  
Ermanno Rolandi ◽  
Alessandra Marabini ◽  
Roberto Franceschini ◽  
Valeria Messina ◽  
Patrizia Bongera ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Serum Cortisol ◽  
Serum Levels ◽  
Significant Rise ◽  
The Other ◽  
Opiate Antagonist ◽  
Pituitary Secretion ◽  
Serum Gh ◽  
Opiate Agonist ◽  
Antagonist Effect

Abstract. The im administration in 6 healthy subjects of buprenorphine, a derivative of the morphine alkaloid thebaine with agonist-antagonist properties, resulted in a significant rise of serum Prl within 45–240 min, a small and transient increase in serum GH and a significant fall in serum cortisol values. Conversely, no appreciable changes in the serum levels of the other hormones studied were found. The observed hormonal effects indicate that, in man, buprenorphine exerts an opiate agonist rather than an opiate antagonist effect.

Somatomedin A levels in patients with Cushing's disease

1981 ◽  
Vol 97 (1) ◽  
pp. 12-17 ◽  
Author(s):  
Marja Thorén ◽  
Kerstin Hall ◽  
Tiit Rähn
Keyword(s):  
Direct Effect ◽  
Cushing’S Disease ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Significant Rise ◽  
Radioreceptor Assay ◽  
Cushing's Disease ◽  
Stereotactic Radiation ◽  
Retarding Effect ◽  
Selective Impairment

Abstract. The serum levels of immunoreactive somatomedin A (SMA) in 23 patients with Cushing's disease, aged 6–61 years, were within the range of healthy subjects for their ages. No correlation was found between SMA and the excretion of cortisol. After im administration of hGH (8 IU = 4 mg) daily for 3 days there was a significant rise in SMA, both determined by radioimmunoassay and radioreceptor assay. Thus no impairment was found in the GH-dependent SMA levels or the ability of hGH to generate somatomedin, which indicates that the growth retarding effect of cortisol is most likely due to a direct effect on the tissue. After treatment with stereotactic radiation to the hypophysis there was a significant decrease in cortisol excretion without any change in SMA levels, indicating the possibility to achieve a selective impairment of the ACTH-cortisol axis.

Regulation of serum spadin propeptide: An antidepressant response probe

2016 ◽  
Vol 33 (S1) ◽  
pp. S417-S417
Author(s):  
J. Mazella ◽  
C. Devader ◽  
M. Roulot ◽  
M. Borsotto ◽  
C. Heurteaux
Keyword(s):  
Serum Level ◽  
Healthy Subjects ◽  
Antidepressant Treatment ◽  
Serum Insulin ◽  
Maximal Activity ◽  
Serum Levels ◽  
Significant Rise ◽  
Detection Range ◽  
Competing Interest ◽  
Depressive Patients

ObjectivesWe previously discovered that spadin, a short analogue of the propeptide (PE) released from the maturation of sortilin, displays potent antidepressant properties. Since the PE level can be measured in the blood, we aimed to investigate how the PE serum concentration is regulated in mice. We wondered whether the PE serum levels vary between healthy subjects and patients with major depressive disorder (MDD).MethodsWe developped a dosing method based on the AlphaScreen™ technology (Perkin) which allow to selectively detect both PE, spadin and metabolic products from these peptides with a detection range of 1 ng/mL.ResultsWe found that insulin significantly up-regulated serum PE concentration from 26.15 ± 2.63 to 41.43 ± 6.27 nM (P = 0.0318). Analysis during circadian cycle in mice revealed that the amount of PE and its derivatives significantly varied during the cycle being higher during the period of maximal activity (dark period). We also measured serum insulin concentration between 1 and 7 pm and observed a significant rise confirming the relationships between insulin and PE concentration. We showed that the serum level of PE is lower in depressive patients than in healthy non-psychiatric. We observed that the weaker level of PE in depressive patients can recover the level of healthy subjects after a chronic antidepressant treatment.ConclusionsDosing the serum level of PE could be a promising approach for the diagnosis of depression and to determine the remission of the disease.Disclosure of interestThe authors have not supplied their declaration of competing interest.

ABNORMAL RESPONSE OF THYROTROPHIN AND GROWTH HORMONE TO THYROTROPHIN RELEASING HORMONE IN CHRONIC RENAL FAILURE

1975 ◽  
Vol 79 (4) ◽  
pp. 635-643 ◽  
Author(s):  
Koichi Hasegawa ◽  
Yoshiki Matsushita ◽  
Seima Otomo ◽  
Noboru Hamada ◽  
Yoshiki Nishizawa ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Healthy Subjects ◽  
Maximum Level ◽  
Serum Levels ◽  
Thyrotrophin Releasing Hormone ◽  
The Mean ◽  
Maximum Increment ◽  
Serum Gh ◽  
Serum Tsh

ABSTRACT Serum levels of TSH and GH were measured by radioimmunoassay after iv injection of 500 μg of TRH in 9 undialysed patients and 12 dialysed patients with chronic renal failure and in 6 healthy subjects. The basal level of the serum TSH was significantly higher in patients with chronic renal failure than that in healthy subjects. In healthy subjects, serum TSH rose to a maximum level 30 min after TRH injection, while in patients with chronic renal failure, serum TSH rose to a maximum level 60 min after TRH injection. The mean maximum increment of serum TSH in healthy subjects was significantly higher than that in patients with chronic renal failure. Although TSH levels rapidly decreased after initial rise at 30 min after TRH administration in healthy subjects, these did not show significant changes at 60 and 120 min compared with values at 30 min after TRH administration in both dialysed and undialysed patients. The basal level of serum GH was significantly higher in dialysed patients with chronic renal failure than in healthy subjects. Serum GH level was much higher in dialysed patients at 30 min after TRH injection compared with that in healthy subjects. These findings may indicate that the response of the pituitary to TRH is abnormal and that the turnover of TSH and GH is decreased in patients with chronic renal failure.

The effect of a met-enkephalin analogue on growth hormone, prolactin, gonadotropins, cortisol and thyroid stimulating hormone in healthy elderly men

1992 ◽  
Vol 127 (3) ◽  
pp. 205-209 ◽  
Author(s):  
M Giusti ◽  
G Delitala ◽  
G Marini ◽  
B Uggias ◽  
P Sessarego ◽  
...  
Keyword(s):  
Young Adults ◽  
Young Men ◽  
Thyroid Stimulating Hormone ◽  
Significant Rise ◽  
The Other ◽  
Cortisol Secretion ◽  
Placebo Administration ◽  
Elderly Men ◽  
Healthy Elderly ◽  
Pituitary Secretion

The aim of the study was to evaluate the effect of the guanyl derivative of the opioid analogue D-ala2,MePhe4-Met-enkephalin-(o)-ol (G-DAMME) on pituitary secretion in healthy elderly men. Nine healthy elderly men (65–88 years) and 10 young adults (20–30 years) were studied. GH, PRL, gonadotropins, cortisol (to evaluate the effect on ACTH) and TSH were measured after G-DAMME (0.25 mg iv) or placebo administration. In elderly men, the GH response to G-DAMME was reduced or absent, while prompt GH release was found in all young men. G-DAMME lowered LH levels in young men but not in elderly men. No significant variations in FSH levels after G-DAMME and placebo were noted in either group of subjects. A similar and significant rise in PRL and TSH, and a fall in cortisol, after G-DAMME was observed in both elderly and young adults. We have demonstrated that the sensitivity to opioid modulation by G-DAMME on PRL, TSH and cortisol secretion is unchanged with aging. On the other hand, the data indicate that LH and GH responsiveness to G-DAMME change with age.

Changes of pituitary secretion after long-term treatment with hydergine, in elderly patients

1983 ◽  
Vol 102 (3) ◽  
pp. 332-336
Author(s):  
Ermanno Rolandi ◽  
Gianni Magnani ◽  
Luigi Bottaro ◽  
Tommaso Barreca
Keyword(s):  
Elderly Patients ◽  
Serum Levels ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Before And After ◽  
Pituitary Secretion ◽  
Serum Gh ◽  
Dopaminergic Stimulation ◽  
Ergot Derivative

Abstract. The aim of this study was to evaluate the effects of long-term treatment with an ergot derivative, dihydroergotoxine mesylate (hydergine) 6 mg/day, on pituitary secretion on 10 elderly patients of both sexes. Samples were drawn at 120 min intervals during a 24 h period, before and after 1 month of therapy. Serum levels of Prl, GH, LH, FSH, TSH and cortisol were measured by RIAs. Hydergine induced a significant increase in the nocturnal serum GH peak. Conversely, no appreciable changes in the pattern of the other hormones studied were found. The observed endocrine effects could be due to the chronic dopaminergic stimulation induced by hydergine.

scholarly journals Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly

2004 ◽  
pp. 27-32 ◽  
Author(s):  
M Arosio ◽  
CL Ronchi ◽  
C Gebbia ◽  
S Pizzinelli ◽  
D Conte ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Energy Homeostasis ◽  
Hormone Secretion ◽  
Serum Cortisol ◽  
Normal Subjects ◽  
Diabetic Patients ◽  
Glucose Levels ◽  
Overnight Fasting ◽  
Design And Methods ◽  
Serum Gh

OBJECTIVE: Ghrelin, a gut-brain peptide involved in the control of energy homeostasis, affects antero-pituitary and gastro-entero-pancreatic (GEP) hormone secretion in healthy subjects. We aimed to verify whether such hormonal responses are retained in acromegaly, a disease characterized by high GH, subnormal ghrelin and abnormal GEP hormone levels. DESIGN AND METHODS: The effect of ghrelin (3.3 microg/kg given after overnight fasting as an i.v. bolus) on GH, prolactin (PRL), adrenocorticotropin (ACTH), cortisol, insulin, glucose, total somatostatin (SS) and pancreatic polypeptide (PP) circulating levels were evaluated in seven non-diabetic patients with newly diagnosed acromegaly and in nine healthy controls. RESULTS: Ghrelin elicited a prompt, marked increase of serum GH and PRL levels in all normal (from 1.6+/-0.6 to 52.9+/-7.8 and from 9.7+/-0.8 to 24.2+/-4.8 microg/l (means+/-S.E.M.), respectively) and acromegalic subjects (from 11.2+/-4.9 to 91.6+/-21.0 and from 42.9+/-26.1 to 113.8+/-79.0 microg/l, respectively). Both plasma ACTH and serum cortisol levels rose significantly in the controls, whereas the cortisol response was blunted in the acromegalic patients. Glucose levels rose earlier and insulin levels fell later in all subjects, with a significantly greater net insulin decrease in acromegalic than in healthy subjects (-80+/-21 vs -17+/-4 pmol/l, P<0.01). A prompt PP rise and a biphasic SS response occurred in all controls, whereas in the acromegalic group the PP response (from 26.1+/-5.0 to 92.2+/-39.0 pmol/l) and the SS response (from 11.9+/-3.0 to 19.7+/-4.0 ng/l) were quite variable. CONCLUSIONS: Ghrelin affects both pituitary and GEP hormones in acromegalic patients as in normal subjects. These findings suggest that ghrelin actions on the energy balance are mediated by complex interactive endocrine loops that involve also the gut and pancreas.

Detection and Quantification of 7-Hydroxydehydroepiandrosterone Epimers in Three Body Fluids

2002 ◽  
Vol 67 (1) ◽  
pp. 10-18 ◽  
Author(s):  
Richard Hampl ◽  
Martin Hill ◽  
Luboslav Stárka
Keyword(s):  
Healthy Subjects ◽  
Serum Levels ◽  
Body Fluids ◽  
Gas Chromatography Mass Spectrometry ◽  
Specific Radioimmunoassay ◽  
Order Of Magnitude ◽  
Three Body ◽  
First Time ◽  
Nanomolar Range ◽  
Detection And Quantification

3β,7α-Dihydroxyandrost-5-en-17-one (1) (7α-OH-DHEA) and its 7β-hydroxy epimer 2 (7β-OH-DHEA) - 7α- and 7β-hydroxydehydroepiandrosterone - were detected and quantified in three human body fluids: in blood serum, saliva and ejaculate. Specific radioimmunoassay and gas chromatography-mass spectrometry have been used. For the first time the data on changes of these dehydroepiandrosterone metabolites are reported for a representative group of healthy subjects of both sexes (172 females and 217 males) during the life span. The serum levels of both 7-hydroxydehydroepiandrosterone epimers in serum and also in semen were in the low nanomolar range, while concentrations by one order of magnitude lower were found in saliva, but still within the detection limit. The results will serve as a basis for comparative studies of 7-hydroxydehydroepiandrosterone levels under various pathophysiological conditions, with a particular respect to autoimmune disorders.

scholarly journals Lipocalin 2 serum levels correlate with age and bone turnover biomarkers in healthy subjects but not in postmenopausal osteoporotic women

Bone Reports ◽  
2021 ◽  
pp. 101059
Author(s):  
Antonio Maurizi ◽  
Marco Ponzetti ◽  
Kaare M. Gautvik ◽  
Sjur Reppe ◽  
Anna Teti ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Lipocalin 2 ◽  
Bone Turnover Biomarkers

scholarly journals Untargeted Plasma Metabolomics Unravels a Metabolic Signature for Tissue Sensitivity to Glucocorticoids in Healthy Subjects: Its Implications in Dietary Planning for a Healthy Lifestyle

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2120
Author(s):  
Nicolas C. Nicolaides ◽  
Maria-Konstantina Ioannidi ◽  
Eleni Koniari ◽  
Ifigeneia Papageorgiou ◽  
Anastasia Bartzeliotou ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Healthy Lifestyle ◽  
Serum Cortisol ◽  
Polyol Pathway ◽  
Gas Chromatography Mass Spectrometry ◽  
Multivariate Statistical ◽  
Glucocorticoid Sensitivity ◽  
Metabolic Signature ◽  
Resistant Group ◽  
One Carbon Metabolism

In clinical practice, differences in glucocorticoid sensitivity among healthy subjects may influence the outcome and any adverse effects of glucocorticoid therapy. Thus, a fast and accurate methodology that could enable the classification of individuals based on their tissue glucocorticoid sensitivity would be of value. We investigated the usefulness of untargeted plasma metabolomics in identifying a panel of metabolites to distinguish glucocorticoid-resistant from glucocorticoid-sensitive healthy subjects who do not carry mutations in the human glucocorticoid receptor (NR3C1) gene. Applying a published methodology designed for the study of glucocorticoid sensitivity in healthy adults, 101 healthy subjects were ranked according to their tissue glucocorticoid sensitivity based on 8:00 a.m. serum cortisol concentrations following a very low-dose dexamethasone suppression test. Ten percent of the cohort, i.e., 11 participants, on each side of the ranking, with no NR3C1 mutations or polymorphisms, were selected, respectively, as the most glucocorticoid-sensitive and most glucocorticoid-resistant of the cohort to be analyzed and compared with untargeted blood plasma metabolomics using gas chromatography–mass spectrometry (GC–MS). The acquired metabolic profiles were evaluated using multivariate statistical analysis methods. Nineteen metabolites were identified with significantly lower abundance in the most sensitive compared to the most resistant group of the cohort, including fatty acids, sugar alcohols, and serine/threonine metabolism intermediates. These results, combined with a higher glucose, sorbitol, and lactate abundance, suggest a higher Cori cycle, polyol pathway, and inter-tissue one-carbon metabolism rate and a lower fat mobilization rate at the fasting state in the most sensitive compared to the most resistant group. In fact, this was the first study correlating tissue glucocorticoid sensitivity with serine/threonine metabolism. Overall, the observed metabolic signature in this cohort implies a worse cardiometabolic profile in the most glucocorticoid-sensitive compared to the most glucocorticoid-resistant healthy subjects. These findings offer a metabolic signature that distinguishes most glucocorticoid-sensitive from most glucocorticoid-resistant healthy subjects to be further validated in larger cohorts. Moreover, they support the correlation of tissue glucocorticoid sensitivity with insulin resistance and metabolic syndrome-associated pathways, further emphasizing the need for nutritionists and doctors to consider the tissue glucocorticoid sensitivity in dietary and exercise planning, particularly when these subjects are to be treated with glucocorticoids.

scholarly journals The Effect of Bilateral Nephrectomy on Renalase and Catecholamines in Hemodialysis Patients

2021 ◽  
Vol 18 (12) ◽  
pp. 6282
Author(s):  
Magda Wiśniewska ◽  
Natalia Serwin ◽  
Violetta Dziedziejko ◽  
Małgorzata Marchelek-Myśliwiec ◽  
Barbara Dołęgowska ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Plasma Concentrations ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Pressure Regulation ◽  
Serum Concentrations ◽  
Monoamine Oxidase Activity ◽  
Normal Kidney ◽  
Bilateral Nephrectomy ◽  
Arterial Blood

Background/Aims: Renalase is an enzyme with monoamine oxidase activity that metabolizes catecholamines; therefore, it has a significant influence on arterial blood pressure regulation and the development of cardiovascular diseases. Renalase is mainly produced in the kidneys. Nephrectomy and hemodialysis (HD) may alter the production and metabolism of renalase. The aim of this study was to examine the effect of bilateral nephrectomy on renalase levels in the serum and erythrocytes of hemodialysis patients. Methods: This study included 27 hemodialysis patients post-bilateral nephrectomy, 46 hemodialysis patients without nephrectomy but with chronic kidney disease and anuria and 30 healthy subjects with normal kidney function. Renalase levels in the serum and erythrocytes were measured using an ELISA kit. Results: Serum concentrations of renalase were significantly higher in post-bilateral nephrectomy patients when compared with those of control subjects (101.1 ± 65.5 vs. 19.6 ± 5.0; p < 0.01). Additionally, renalase concentrations, calculated per gram of hemoglobin, were significantly higher in patients after bilateral nephrectomy in comparison with those of healthy subjects (994.9 ± 345.5 vs. 697.6 ± 273.4, p = 0.015). There were no statistically significant differences in plasma concentrations of noradrenaline or adrenaline. In contrast, the concentration of dopamine was significantly lower in post-nephrectomy patients when compared with those of healthy subjects (116.8 ± 147.7 vs. 440.9 ± 343.2, p < 0.01). Conclusions: Increased serum levels of renalase in post-bilateral nephrectomy hemodialysis patients are likely related to production in extra-renal organs as a result of changes in the cardiovascular system and hypertension.

Sign in / Sign up

Export Citation Format

Share Document